Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Cash & Equivalents (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Cash & Equivalents for 8 consecutive years, with $648.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 27.22% year-over-year to $648.3 million, compared with a TTM value of $648.3 million through Sep 2025, down 27.22%, and an annual FY2024 reading of $879.5 million, up 67.07% over the prior year.
  • Cash & Equivalents was $648.3 million for Q3 2025 at Bicycle Therapeutics, down from $721.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $961.4 million in Q2 2024 and bottomed at $195.9 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $541.2 million, with a median of $457.0 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents dropped 27.88% in 2023, then skyrocketed 182.39% in 2024.
  • Year by year, Cash & Equivalents stood at $438.7 million in 2021, then dropped by 22.69% to $339.2 million in 2022, then surged by 55.22% to $526.4 million in 2023, then skyrocketed by 67.07% to $879.5 million in 2024, then fell by 26.29% to $648.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for BCYC at $648.3 million in Q3 2025, $721.5 million in Q2 2025, and $793.0 million in Q1 2025.